FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, ...
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma Using primary samples from the InterMEL study, a retrospective cohort of cases ...
Presentations showcase AI-powered multimodal analytics that unblind tumor biology and accelerate drug developmentWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback